FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136105674> ?p ?o ?g. }

• W3136105674 endingPage "2161" @default.
• W3136105674 startingPage "2149" @default.
• W3136105674 abstract "Although immunotherapy works well in parts of patients with bladder cancer (BLCA), its overall response rate of anti-PD-1 inhibitors remains unsatisfactory. Besides, growing evidence shows that tumor-infiltrating lymphocytes (TILs) immunotherapy has demonstrated excellent efficacy in various cancers. Considering the huge heterogeneity and low overall survival rate of BLCA, it is urgent to explore the new immune checkpoints (ICs) or TILs therapy to improve the survival prognosis for BLCA patients.The public bioinformatics databases were used to explore the prognostic value of 5 potential ICs targets (TIM-3, LAG-3, OX40, 4-1BB and CD39). A total of 46 BLCA patients undergoing surgical treatment at our hospital from May 2020 to October 2020 were enrolled in this study. The expressions of PD-1, TIM-3, LAG-3, OX40, 4-1BB, and CD39 in T cells of BLCA patients were explored by flow cytometry, and the correlation between different subgroups of T cells and clinicopathological parameters was analyzed. Besides, the mouse CD4+CD39+ T cells, CD4+CD39- T cells, CD8+CD39+ T cells, and CD8+CD39- T cells were sorted and co-cultured with MB49 bladder cancer cell lines in vitro to investigate the potential biomarker of tumor-reactive TILs.Public bioinformatics databases analyses show that only the high expression of CD39 was significantly associated with advanced tumor stage (P < 0.001) and tend to result in a worse survival rate. In our study, the elevated expression of CD39 in CD4+/CD8+ T cells were significantly associated with the pathological T stage (pT <2, P = 0.041) and papillary tumor (P = 0.038). Moreover, the CD8+CD39+ T cells showed a stronger tumor-killing effect and produced a higher level of IFN-γ than other T cell populations.CD39 may be a potential prognostic marker in BLCA, and CD8+CD39+ T cells may be selected as tumor-reactive and killing T cells for TILs therapy." @default.
• W3136105674 created "2021-03-29" @default.
• W3136105674 creator A5009054311 @default.
• W3136105674 creator A5010247484 @default.
• W3136105674 creator A5019370162 @default.
• W3136105674 creator A5040923103 @default.
• W3136105674 creator A5044825639 @default.
• W3136105674 creator A5046276266 @default.
• W3136105674 creator A5055111969 @default.
• W3136105674 date "2021-03-01" @default.
• W3136105674 modified "2023-10-14" @default.
• W3136105674 title "CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer" @default.
• W3136105674 cites W1868820697 @default.
• W3136105674 cites W1872256430 @default.
• W3136105674 cites W1877911682 @default.
• W3136105674 cites W1980137951 @default.
• W3136105674 cites W1990013942 @default.
• W3136105674 cites W1993334366 @default.
• W3136105674 cites W2013177587 @default.
• W3136105674 cites W2082902034 @default.
• W3136105674 cites W2086970364 @default.
• W3136105674 cites W2095864883 @default.
• W3136105674 cites W2105459360 @default.
• W3136105674 cites W2132923173 @default.
• W3136105674 cites W2135744728 @default.
• W3136105674 cites W2137395995 @default.
• W3136105674 cites W2148605435 @default.
• W3136105674 cites W2155959680 @default.
• W3136105674 cites W2272984102 @default.
• W3136105674 cites W2403400382 @default.
• W3136105674 cites W2529300207 @default.
• W3136105674 cites W2530516001 @default.
• W3136105674 cites W2591655768 @default.
• W3136105674 cites W2607129810 @default.
• W3136105674 cites W2736730167 @default.
• W3136105674 cites W2765132620 @default.
• W3136105674 cites W2767731416 @default.
• W3136105674 cites W2767819563 @default.
• W3136105674 cites W2804073610 @default.
• W3136105674 cites W2807534769 @default.
• W3136105674 cites W2808293799 @default.
• W3136105674 cites W2849303123 @default.
• W3136105674 cites W2864786814 @default.
• W3136105674 cites W2884754721 @default.
• W3136105674 cites W2889646458 @default.
• W3136105674 cites W2946980810 @default.
• W3136105674 cites W2947495476 @default.
• W3136105674 cites W2997386439 @default.
• W3136105674 cites W3032544096 @default.
• W3136105674 cites W3046015080 @default.
• W3136105674 cites W3093151963 @default.
• W3136105674 doi "https://doi.org/10.2147/ott.s297272" @default.
• W3136105674 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8006912" @default.
• W3136105674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33790578" @default.
• W3136105674 hasPublicationYear "2021" @default.
• W3136105674 type Work @default.
• W3136105674 sameAs 3136105674 @default.
• W3136105674 citedByCount "14" @default.
• W3136105674 countsByYear W31361056742021 @default.
• W3136105674 countsByYear W31361056742022 @default.
• W3136105674 countsByYear W31361056742023 @default.
• W3136105674 crossrefType "journal-article" @default.
• W3136105674 hasAuthorship W3136105674A5009054311 @default.
• W3136105674 hasAuthorship W3136105674A5010247484 @default.
• W3136105674 hasAuthorship W3136105674A5019370162 @default.
• W3136105674 hasAuthorship W3136105674A5040923103 @default.
• W3136105674 hasAuthorship W3136105674A5044825639 @default.
• W3136105674 hasAuthorship W3136105674A5046276266 @default.
• W3136105674 hasAuthorship W3136105674A5055111969 @default.
• W3136105674 hasBestOaLocation W31361056741 @default.
• W3136105674 hasConcept C121608353 @default.
• W3136105674 hasConcept C126322002 @default.
• W3136105674 hasConcept C143998085 @default.
• W3136105674 hasConcept C146357865 @default.
• W3136105674 hasConcept C151730666 @default.
• W3136105674 hasConcept C154317977 @default.
• W3136105674 hasConcept C167672396 @default.
• W3136105674 hasConcept C202751555 @default.
• W3136105674 hasConcept C203014093 @default.
• W3136105674 hasConcept C2777701055 @default.
• W3136105674 hasConcept C2778326572 @default.
• W3136105674 hasConcept C2780352672 @default.
• W3136105674 hasConcept C502942594 @default.
• W3136105674 hasConcept C553184892 @default.
• W3136105674 hasConcept C55493867 @default.
• W3136105674 hasConcept C71924100 @default.
• W3136105674 hasConcept C86803240 @default.
• W3136105674 hasConcept C8891405 @default.
• W3136105674 hasConceptScore W3136105674C121608353 @default.
• W3136105674 hasConceptScore W3136105674C126322002 @default.
• W3136105674 hasConceptScore W3136105674C143998085 @default.
• W3136105674 hasConceptScore W3136105674C146357865 @default.
• W3136105674 hasConceptScore W3136105674C151730666 @default.
• W3136105674 hasConceptScore W3136105674C154317977 @default.
• W3136105674 hasConceptScore W3136105674C167672396 @default.
• W3136105674 hasConceptScore W3136105674C202751555 @default.
• W3136105674 hasConceptScore W3136105674C203014093 @default.
• W3136105674 hasConceptScore W3136105674C2777701055 @default.

• next